Robert Mitchnick, BlackRock's global head of digital assets and creator of the iShares Bitcoin Trust ETF, will speak at the Bitcoin Treasuries Conference in New York City on September 28. The event, limited to 300 attendees, focuses on corporate Bitcoin strategy and has previously facilitated major Bitcoin deals. Mitchnick's participation is notable as he will discuss key topics like custody, ETF versus direct Bitcoin holdings, and crypto mergers, offering insights from his experience leading BlackRock's digital assets business since 2018.
BlackRock's digital assets chief Robert Mitchnick will speak at the Bitcoin Treasuries Conference in New York City on September 28. For readers following major cryptocurrencies, here is Pluang's market snapshot as of Sep 15, 2026 08:52 WIB: Of 50 major cryptocurrencies priced on Pluang, 32 rose and 17 fell today. Notable movers include AVAX at Rp133.312 (+3.50%, 73% Sell / 27% Buy), SOL at Rp1.806.964 (+3.42%, 50% Sell / 50% Buy), and LINK at Rp204.506 (+3.33%, 1% Sell / 99% Buy).
The European Medicines Agency's CHMP has recommended approval for Johnson & Johnson's TALVEY® (talquetamab) in combination with daratumumab for treating relapsed or refractory multiple myeloma (RRMM) in patients who have had at least one prior therap...
Fortrea Holdings and Omico have formed a partnership to accelerate precision oncology research in Australia by combining Fortrea's clinical trial expertise with Omico's Precision Oncology Screening Platform (PrOSPeCT). This collaboration aims to impr...
Fortrea Holdings and Omico have formed a partnership to enhance precision oncology research in Australia by linking cancer patients to biomarker-matched clinical trials. This collaboration combines Fortrea's oncology trial expertise with Omico's Prec...
Fortrea Holdings Inc and Omico have formed a partnership to accelerate precision oncology research in Australia by connecting cancer patients to biomarker-driven clinical trials. The collaboration combines Fortrea's expertise in oncology clinical tri...
Fortrea Holdings Inc and Omico have formed a partnership to enhance precision oncology research in Australia by matching cancer patients with biomarker-driven clinical trials. This collaboration combines Fortrea's expertise in oncology clinical trial...
